^
Association details:
| Biomarker: | PD-L1 expression + PVR expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer
Published date:
03/09/2022
Excerpt:
The patients with CD155 positive had a significantly worse response to αPD1 therapy compared to CD155 negative patients (ORR: 25.6% vs 54.8%, P<0.01; median PFS: 5.1 vs 7.1 months, HR=2.322; 95% CI 1.396-3.861, P=0.001). This effect is more prominent in PD-L1 positive patients. In PD-L1 positive patients, CD155 expression is associated with a poor response to αPD1 therapy in both LUAC (lung adenocarcinoma) and LUSC (lung squamous cell carcinoma)...
DOI:
https://doi.org/10.1093/cei/uxac020
